A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to determine the maximum tolerated dose and/or a biologically active dose. The study will be conducted in multiple sites and test increasing doses of AMG 330. The safety of subjects will be monitored by intensive assessment of vital signs, electrocardiograms, physical examinations, and laboratory tests.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02520427.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationAmgen, Inc.

• Primary ID20120252
• Secondary IDsNCI-2015-01427, 2014-004462-20
• ClinicalTrials.gov IDNCT02520427